Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
30 Abril 2024 - 7:00AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine and wellness company, today
announced the results of its most recent Truvaga Plus consumer
study conducted earlier this year. Based on a 30-day in-home use
test by an independent third-party research firm, Truvaga Plus
helped its users improve sleep, focus, stress, energy, and mood.
39 participants were instructed to use the Truvaga Plus product
at home twice a day for 30 days to assess the product's benefits,
efficacy, and overall user experience. Self-assessment evaluations
were reported after 7 and 30 days. After 30 days, users reported
the following:
- 82% felt calmer;
- 82% felt mentally healthier;
- 77% felt more alert;
- 77% felt more relaxed;
- 74% felt they sleep better
- 74% felt their mood improved; and
- 67% had more energy
Of those that felt they slept better, 72% reported they received
between 30 minutes to 2+ hours or more sleep each night.
“I started using the product with not much expectation because
of how simple it seemed,” said [one/Abhinav G. a] study
participant. “But I was pleasantly surprised that something so easy
to use and that has no harmful effects, actually helps me sleep
better and have lower stress.”
After the study completed, 87% of users said they were likely to
continue to use Truvaga Plus for ongoing overall wellness
benefits.
“We are thrilled with the results of the Truvaga Plus consumer
study,” stated Dan Goldberger, Chief Executive Officer at
electroCore. “The remarkable positive benefits, and complete lack
of problems reported by study participants using Truvaga Plus is
very exciting for future adoption of our health and wellness
product offerings.”
For more information on Truvaga Plus and study results visit our
website, truvaga.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
and wellness company dedicated to improving health and promoting
general wellness through its non-invasive vagus nerve stimulation
(“nVNS”) technology platform. The company’s is focused on the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About Truvaga Plus
Truvaga Plus is a revolutionary handheld vagus nerve stimulator
that utilizes the company’s proven technology to quickly and gently
activate the vagus nerve. It’s designed to work with the body to
balance the nervous system to feel calmer, think clearer, and sleep
better. Truvaga Plus is intended for general health and wellness
purposes only and is not intended to diagnose, cure, mitigate,
treat, or prevent any disease.
For more information, please visit www.truvaga.com.
Forward-Looking Statements
This press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects, new and existing wellness product offerings, new
ecommerce site, and clinical and product development plans; its
pipeline or potential markets for its technologies; the timing,
outcome and impact of regulatory, clinical and commercial
developments including focus group study results; the Company’s
business prospects in the United States (including its e-commerce
initiatives) and other new markets and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "will," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the ability to successfully
launch and commercialize Truvaga Plus, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
electroCore (NASDAQ:ECOR)
Gráfica de Acción Histórica
De May 2023 a May 2024